fgf2  (Proteintech)

Journal: Bioactive Materials

Article Title: Bioinspired scaffold recapitulating chondrogenic ontogeny and microenvironment for functional cartilage regeneration

doi: 10.1016/j.bioactmat.2025.11.041

Figure Lengend Snippet: Spatiotemporal remodeling of FGF signaling networks in chondrocyte-like subpopulations. A) Heatmap of FGF signaling mediated communication patterns across chondrocyte-like subpopulations. B) Circle plot visualizing differential inter-subpopulation communication of FGF ligand-receptor signaling in chondrocyte-like cells at 4 week. C) Circle plot visualizing differential inter-subpopulation communication of FGF ligand-receptor signaling in chondrocyte-like cells at 8 week. D) Violin plots of expressions of FGF genes. E) Bubble plot of dysregulated ligand-receptor pairs. F) The differences in the overall information flow in the network. G) Representative western blots showing protein levels of FGF2 and FGF18 in Control and CE-SKP co-cultured cells.

Article Snippet: After blocking the membranes for an hour at room temperature using fast blocking solution, the membranes were incubated with primary antibodies specific for SOX9 (1:2000, 67439-1-Ig, Proteintech), COL2 (1:200, NBP1-91056, Novus Biologicals), COL10 (1:500, 26984-1-AP, Proteintech), COL1 (1:2000, 67288-1-Ig, Proteintech), RUNX2 (1:200, 20700-1-AP, Proteintech), FGF2 (1:500, 11234-1-AP, Proteintech), FGF18 (1:500, 60341-1-Ig, Proteintech) and GAPDH (1:50000, 60004-1-Ig, Proteintech) for an entire night at 4 °C.

Techniques: Western Blot, Control, Cell Culture

Journal: British Journal of Cancer

Article Title: Fibroblast growth factor signals drive the metastatic behavior in small cell lung cancer

doi: 10.1038/s41416-025-03276-y

Figure Lengend Snippet: a Pooled data of sprouting inhibition compared to DMSO controls after 120 h of sprouter cell lines (HLHE, H196, H372, H1341) after treatment with FGFR inhibitor erdafitinib, EGFR inhibitor erlotinib, TGFβR inhibitor galunisertib and SB-431542, EZH2 inhibitor GSK2816126A (GSK126), VEGFR1-3 inhibitor KRN-633, YAP1/TAZ and TEAD inhibitor K-975, VEGFR1-3, FGFR1-3, PDGFR inhibitor nintedanib, PDGFRα, β inhibitor seralutinib, MST1/2 inhibitor XMU-MP-1 and PORCN inhibitor Wnt-C59. Each dot represents one cell line. Statistical evaluation was performed using one-way ANOVA and DUNN´s multiple comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001 b Representative images of sprouting ability of HLHE cells with control (DMSO, upper panel) and nintedanib (0.5 µM, lower panel) treatment after 24 h, 96 h, and 120 h. Scale bar: 500 µm. c Quantification of sprouting based on spheroid sprouting assays with reduced serum (2.5% FBS). Spheroids were treated with 10 ng/ml and 50 ng/ml recombinant FGF2 for 96 h. Mean sprout length over time is shown as mean ± SEM of at least 10 individual spheroids. Two-way ANOVA and Tukey´s multiple comparison test. *** p < 0.001. d RNA expression of FGFRs and FGFs in pooled non-sprouter (ochre) and non-sprouter (blue) cell lines ( n = 4), determined by qPCR. Data is shown as mean ± SEM. Mann-Whitney test. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: TaqMan assay IDs used in this study comprised FGF-1, Hs01106908_m1, FGF-2, Hs00266645_m1, FGF-5, Hs00170454_m1, FGF-18, Hs00826077_m1, FGFR1, Hs00915142_m1, FGFR2, Hs01552918_m1, FGFR3, Hs00179829_m1, FGFR4 and Hs01106908_m1.

Techniques: Inhibition, Comparison, Control, Recombinant, RNA Expression, MANN-WHITNEY